글로벌 항비만제 시장 (2023-2032) : 처방약, 일반 의약품

■ 영문 제목 : Anti-Obesity Drugs Market By Drug Type (Prescription Drugs, Over The Counter Drugs), By Mechanism of Action (Centrally Acting Anti-Obesity Drugs, Peripherally Acting Anti-Obesity Drugs), By Route of Administration (Oral Route, Subcutaneous Route), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2023-2032

Allied Market Research가 발행한 조사보고서이며, 코드는 ALD23SEP113 입니다.■ 상품코드 : ALD23SEP113
■ 조사/발행회사 : Allied Market Research
■ 발행일 : 2023년 4월
■ 페이지수 : 447
■ 작성언어 : 영어
■ 보고서 형태 : PDF
■ 납품 방식 : E메일
■ 조사대상 지역 : 세계
■ 판매가격 / 옵션 (부가세 10% 별도)
Single UserUSD5,820 ⇒환산￦7,857,000견적의뢰/주문/질문
5 UserUSD6,540 ⇒환산￦8,829,000견적의뢰/주문/질문
Enterprise UserUSD9,870 ⇒환산￦13,324,500견적의뢰/구입/질문
※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.
글로벌 항비만제 시장은 2022년 1,605.36백만 달러 규모였으며, 2023년부터 2032년까지 10.7%의 연평균 성장률을 보이며 2032년에는 4,439.34백만 달러에 달할 것으로 예상됩니다. 비만은 건강에 부정적인 영향을 미칠 정도로 체지방이 과도하게 축적된 의학적 상태입니다. 일반적으로 체질량 지수(BMI)가 30 이상인 것으로 정의됩니다. 선진국과 개발도상국에서 가장 크고 빠르게 성장하는 공중 보건 문제로 널리 인식되고 있습니다. 항비만제는 과체중인 사람들을 돕기 위해 처방되는 약물입니다. 이러한 약물은 식욕을 억제하거나 신진대사를 증가시키거나 음식에서 지방이 흡수되는 것을 차단하는 방식으로 작용합니다. 일반적으로 처방되는 항비만제에는 펜터민, 시부트라민, 오르리스타트, 리라글루타이드 등이 있습니다.
항비만제 시장의 성장을 주도하는 주요 요인은 비만 유병률의 상당한 증가, 과체중 또는 비만과 관련된 건강 위험의 급증, 비만과 제 2 형 당뇨병을 모두 표적으로하는 여러 잠재적 약물 분자에 대한 연구 개발 활동의 증가입니다. 예를 들어, 노보 노디스크는 2021년 6월 미국 식품의약국(FDA)이 만성 체중 관리를 위해 주 1회 세마글루타이드 2.4mg 주사제인 웨고비를 미국에서 승인했다고 발표했습니다. 또한, 비만과 관련된 건강 관련 문제를 사람들에게 알리기 위해 정부가 취한 이니셔티브의 수가 증가하고 항비만제의 대규모 생산을 위한 정부 및 민간 기관의 자금이 증가함에 따라 시장 성장을 주도하는 주요 기업에게 새로운 시장 잠재력이 열릴 수 있습니다.

그러나 엄격한 약물 승인 정책과 대체 요법의 가용성은 시장 성장을 방해합니다. 반대로 비만과 제 2 형 당뇨병의 유병률이 증가함에 따라 시장의 연구자와 공급 업체는 비만과 제 2 형 당뇨병에 모두 대응할 수있는 약물을 연구하도록 장려하고 있습니다. 따라서 비만 인구의 증가, 건강에 해로운 식습관의 증가, 앉아있는 생활 방식은 항비만제에 대한 새로운 시장 잠재력을 열 수 있으며 예측 기간 동안 시장 성장을위한 수익성있는 기회를 제공 할 것으로 예상됩니다. 

북미는 2021년 항비만제 시장 점유율의 대부분을 차지했으며 예측 기간 동안 지배적인 위치를 유지할 것으로 예상됩니다. 항비만제 시장은 주로 비만 인구의 증가와 항비만제에 대한 높은 의료비 지출에 의해 주도됩니다. 또한 비만과 관련된 중증 만성 질환에 대한 인구의 인식이 증가하고 주요 시장 참여자의 R&D 활동에 대한 투자 증가로 인해 임상 시험 수가 급증하여 시장 성장을 촉진 할 것으로 예상됩니다.

아시아 태평양 지역은 의료 지출 증가와 아시아 태평양 지역의 비만 치료를 위한 신약 개발을위한 주요 시장 참여자들의 R&D 활동 급증으로 인해 예측 기간 동안 가장 빠른 CAGR을 기록 할 것으로 예상됩니다. 또한 인도, 중국, 한국과 같은 개발 도상국에서 비만 유병률의 증가와 항비만제에 대한 인식의 증가는이 지역의 항비만제 시장의 성장에 기여합니다.

그러나 시장은 비만 유병률 증가로 인해 대유행 이후 회복을 목격 할 것으로 예상됩니다. 또한 대유행 기간 동안 건강에 해롭고 앉아있는 생활 방식을 채택하는 사람들의 수가 증가함에 따라 시장 성장이 촉진 될 것으로 예상됩니다.
항비만제 시장은 약물 유형, 작용 기전, 투여 경로, 유통 채널 및 지역을 기준으로 세분화됩니다. 약물 유형별로 시장은 처방약과 일반 의약품으로 나뉩니다. 작용 기전별로 시장은 중추 작용 비만 약물과 말초 작용 비만 약물로 나뉩니다. 투여 경로에 따라 시장은 경구 경로와 피하 경로로 분류됩니다. 유통 채널별로 시장은 병원 약국, 소매 약국 및 온라인 약국으로 분류됩니다. 지역별로 시장은 북미, 유럽, 아시아 태평양 및 중남미/중동/아프리카에서 분석됩니다.

항비만제 시장에서 활동하는 주요 업체는 Currax Pharmaceuticals LLC, Pfizer Inc, Novo Nordisk A/S, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, KVK Tech Inc, CHEPLAPHARM Arzneimittel GmbH, Gelesis Holdings, INC., VIVUS LLC, 및 Rhythm Pharmaceuticals. 등이 있습니다.

이해관계자를 위한 주요 이점
이 보고서는 2022년부터 2032년까지 항비만제 시장 분석의 시장 부문, 현재 동향, 추정치 및 역학에 대한 정량적 분석을 제공하여 일반적인 항비만제 시장 기회를 식별합니다.
시장 조사는 주요 동인, 제약 및 기회와 관련된 정보와 함께 제공됩니다.
포터의 다섯 가지 경쟁 요인 분석은 이해 관계자가 이익 지향적인 비즈니스 결정을 내리고 공급 업체-구매자 네트워크를 강화할 수 있도록 구매자와 공급 업체의 잠재력을 강조합니다.
항비만제 시장 세분화에 대한 심층 분석은 일반적인 시장 기회를 결정하는 데 도움이 됩니다.
각 지역의 주요 국가는 글로벌 시장에 대한 매출 기여도에 따라 매핑됩니다.
시장 플레이어 포지셔닝은 벤치마킹을 용이하게하고 시장 플레이어의 현재 위치에 대한 명확한 이해를 제공합니다.
이 보고서에는 지역 및 항비만제 시장 동향, 주요 업체, 시장 부문, 응용 분야 및 시장 성장 전략에 대한 분석이 포함되어 있습니다.

주요 시장 부문
약물 유형별
처방약
일반 의약품

작용 메커니즘별
중추 작용 항비만제
말초 작용 항비만제

투여 경로별
경구 경로
피하 경로

유통 채널별
병원 약국
소매 약국
온라인 약국

지역별
북미
미국
캐나다
멕시코
유럽
독일
프랑스
영국
이탈리아
스페인
기타 유럽 지역
아시아 태평양
일본
중국
호주
인도
한국
기타 아시아 태평양 지역
중남미/중동/아프리카
브라질
사우디 아라비아
남아프리카 공화국
기타 중동 및 아프리카 지역

주요 기업
○ Pfizer Inc.
○ Novo Nordisk A/S
○ Boehringer Ingelheim International GmbH
○ KVK Tech Inc.
○ Gelesis Holdings, INC.
○ Vivus LLC.
○ Currax Pharmaceuticals LLC
○ GlaxoSmithKline plc
○ CHEPLAPHARM Arzneimittel GmbH
○ Rhythm Pharmaceuticals
■ 보고서 개요

CHAPTER 1 : 소개
CHAPTER 2 : 개요
CHAPTER 3 : 시장 동향
CHAPTER 4 : 항비만제 시장, 약품 유형별
CHAPTER 5 : 항비만제 시장, 작용 기전별
CHAPTER 6 : 항비만제 시장, 투여 경로별
CHAPTER 7 : 항비만제 시장, 유통 채널별
CHAPTER 8 : 항비만제 시장, 지역별
CHAPTER 9 : 경쟁 현황
CHAPTER 10 : 기업 정보

■ 보고서 목차

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in the prevalence of obesity
3.4.1.2. Increase in number of drugs in pipeline
3.4.1.3. Increase in number of clinical trials

3.4.2. Restraints
3.4.2.1. Potential side effects of anti-obesity drugs

3.4.3. Opportunities
3.4.3.1. High growth potential in developing economies

3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Prescription Drugs
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Over The Counter Drugs
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
CHAPTER 5: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION
5.1. Overview
5.1.1. Market size and forecast
5.2. Centrally Acting Anti-Obesity Drugs
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Peripherally Acting Anti-Obesity Drugs
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Oral Route
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Subcutaneous Route
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
CHAPTER 7: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL
7.1. Overview
7.1.1. Market size and forecast
7.2. Hospital Pharmacies
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis by country
7.3. Retail Pharmacies
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market share analysis by country
7.4. Online Pharmacies
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by region
7.4.3. Market share analysis by country
CHAPTER 8: ANTI-OBESITY DRUGS MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast By Region
8.2. North America
8.2.1. Key trends and opportunities
8.2.2. Market size and forecast, by Drug Type
8.2.3. Market size and forecast, by Mechanism of Action
8.2.4. Market size and forecast, by Route of Administration
8.2.5. Market size and forecast, by Distribution Channel
8.2.6. Market size and forecast, by country
8.2.6.1. U.S.
8.2.6.1.1. Key market trends, growth factors and opportunities
8.2.6.1.2. Market size and forecast, by Drug Type
8.2.6.1.3. Market size and forecast, by Mechanism of Action
8.2.6.1.4. Market size and forecast, by Route of Administration
8.2.6.1.5. Market size and forecast, by Distribution Channel
8.2.6.2. Canada
8.2.6.2.1. Key market trends, growth factors and opportunities
8.2.6.2.2. Market size and forecast, by Drug Type
8.2.6.2.3. Market size and forecast, by Mechanism of Action
8.2.6.2.4. Market size and forecast, by Route of Administration
8.2.6.2.5. Market size and forecast, by Distribution Channel
8.2.6.3. Mexico
8.2.6.3.1. Key market trends, growth factors and opportunities
8.2.6.3.2. Market size and forecast, by Drug Type
8.2.6.3.3. Market size and forecast, by Mechanism of Action
8.2.6.3.4. Market size and forecast, by Route of Administration
8.2.6.3.5. Market size and forecast, by Distribution Channel
8.3. Europe
8.3.1. Key trends and opportunities
8.3.2. Market size and forecast, by Drug Type
8.3.3. Market size and forecast, by Mechanism of Action
8.3.4. Market size and forecast, by Route of Administration
8.3.5. Market size and forecast, by Distribution Channel
8.3.6. Market size and forecast, by country
8.3.6.1. Germany
8.3.6.1.1. Key market trends, growth factors and opportunities
8.3.6.1.2. Market size and forecast, by Drug Type
8.3.6.1.3. Market size and forecast, by Mechanism of Action
8.3.6.1.4. Market size and forecast, by Route of Administration
8.3.6.1.5. Market size and forecast, by Distribution Channel
8.3.6.2. France
8.3.6.2.1. Key market trends, growth factors and opportunities
8.3.6.2.2. Market size and forecast, by Drug Type
8.3.6.2.3. Market size and forecast, by Mechanism of Action
8.3.6.2.4. Market size and forecast, by Route of Administration
8.3.6.2.5. Market size and forecast, by Distribution Channel
8.3.6.3. UK
8.3.6.3.1. Key market trends, growth factors and opportunities
8.3.6.3.2. Market size and forecast, by Drug Type
8.3.6.3.3. Market size and forecast, by Mechanism of Action
8.3.6.3.4. Market size and forecast, by Route of Administration
8.3.6.3.5. Market size and forecast, by Distribution Channel
8.3.6.4. Italy
8.3.6.4.1. Key market trends, growth factors and opportunities
8.3.6.4.2. Market size and forecast, by Drug Type
8.3.6.4.3. Market size and forecast, by Mechanism of Action
8.3.6.4.4. Market size and forecast, by Route of Administration
8.3.6.4.5. Market size and forecast, by Distribution Channel
8.3.6.5. Spain
8.3.6.5.1. Key market trends, growth factors and opportunities
8.3.6.5.2. Market size and forecast, by Drug Type
8.3.6.5.3. Market size and forecast, by Mechanism of Action
8.3.6.5.4. Market size and forecast, by Route of Administration
8.3.6.5.5. Market size and forecast, by Distribution Channel
8.3.6.6. Rest of Europe
8.3.6.6.1. Key market trends, growth factors and opportunities
8.3.6.6.2. Market size and forecast, by Drug Type
8.3.6.6.3. Market size and forecast, by Mechanism of Action
8.3.6.6.4. Market size and forecast, by Route of Administration
8.3.6.6.5. Market size and forecast, by Distribution Channel
8.4. Asia-Pacific
8.4.1. Key trends and opportunities
8.4.2. Market size and forecast, by Drug Type
8.4.3. Market size and forecast, by Mechanism of Action
8.4.4. Market size and forecast, by Route of Administration
8.4.5. Market size and forecast, by Distribution Channel
8.4.6. Market size and forecast, by country
8.4.6.1. Japan
8.4.6.1.1. Key market trends, growth factors and opportunities
8.4.6.1.2. Market size and forecast, by Drug Type
8.4.6.1.3. Market size and forecast, by Mechanism of Action
8.4.6.1.4. Market size and forecast, by Route of Administration
8.4.6.1.5. Market size and forecast, by Distribution Channel
8.4.6.2. China
8.4.6.2.1. Key market trends, growth factors and opportunities
8.4.6.2.2. Market size and forecast, by Drug Type
8.4.6.2.3. Market size and forecast, by Mechanism of Action
8.4.6.2.4. Market size and forecast, by Route of Administration
8.4.6.2.5. Market size and forecast, by Distribution Channel
8.4.6.3. Australia
8.4.6.3.1. Key market trends, growth factors and opportunities
8.4.6.3.2. Market size and forecast, by Drug Type
8.4.6.3.3. Market size and forecast, by Mechanism of Action
8.4.6.3.4. Market size and forecast, by Route of Administration
8.4.6.3.5. Market size and forecast, by Distribution Channel
8.4.6.4. India
8.4.6.4.1. Key market trends, growth factors and opportunities
8.4.6.4.2. Market size and forecast, by Drug Type
8.4.6.4.3. Market size and forecast, by Mechanism of Action
8.4.6.4.4. Market size and forecast, by Route of Administration
8.4.6.4.5. Market size and forecast, by Distribution Channel
8.4.6.5. South Korea
8.4.6.5.1. Key market trends, growth factors and opportunities
8.4.6.5.2. Market size and forecast, by Drug Type
8.4.6.5.3. Market size and forecast, by Mechanism of Action
8.4.6.5.4. Market size and forecast, by Route of Administration
8.4.6.5.5. Market size and forecast, by Distribution Channel
8.4.6.6. Rest of Asia-Pacific
8.4.6.6.1. Key market trends, growth factors and opportunities
8.4.6.6.2. Market size and forecast, by Drug Type
8.4.6.6.3. Market size and forecast, by Mechanism of Action
8.4.6.6.4. Market size and forecast, by Route of Administration
8.4.6.6.5. Market size and forecast, by Distribution Channel
8.5. LAMEA
8.5.1. Key trends and opportunities
8.5.2. Market size and forecast, by Drug Type
8.5.3. Market size and forecast, by Mechanism of Action
8.5.4. Market size and forecast, by Route of Administration
8.5.5. Market size and forecast, by Distribution Channel
8.5.6. Market size and forecast, by country
8.5.6.1. Brazil
8.5.6.1.1. Key market trends, growth factors and opportunities
8.5.6.1.2. Market size and forecast, by Drug Type
8.5.6.1.3. Market size and forecast, by Mechanism of Action
8.5.6.1.4. Market size and forecast, by Route of Administration
8.5.6.1.5. Market size and forecast, by Distribution Channel
8.5.6.2. Saudi Arabia
8.5.6.2.1. Key market trends, growth factors and opportunities
8.5.6.2.2. Market size and forecast, by Drug Type
8.5.6.2.3. Market size and forecast, by Mechanism of Action
8.5.6.2.4. Market size and forecast, by Route of Administration
8.5.6.2.5. Market size and forecast, by Distribution Channel
8.5.6.3. South Africa
8.5.6.3.1. Key market trends, growth factors and opportunities
8.5.6.3.2. Market size and forecast, by Drug Type
8.5.6.3.3. Market size and forecast, by Mechanism of Action
8.5.6.3.4. Market size and forecast, by Route of Administration
8.5.6.3.5. Market size and forecast, by Distribution Channel
8.5.6.4. Rest of LAMEA
8.5.6.4.1. Key market trends, growth factors and opportunities
8.5.6.4.2. Market size and forecast, by Drug Type
8.5.6.4.3. Market size and forecast, by Mechanism of Action
8.5.6.4.4. Market size and forecast, by Route of Administration
8.5.6.4.5. Market size and forecast, by Distribution Channel
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top player positioning, 2022
CHAPTER 10: COMPANY PROFILES
10.1. Currax Pharmaceuticals LLC
10.1.1. Company overview
10.1.2. Key Executives
10.1.3. Company snapshot
10.1.4. Operating business segments
10.1.5. Product portfolio
10.1.6. Key strategic moves and developments
10.2. KVK Tech Inc.
10.2.1. Company overview
10.2.2. Key Executives
10.2.3. Company snapshot
10.2.4. Operating business segments
10.2.5. Product portfolio
10.3. Gelesis Holdings, INC.
10.3.1. Company overview
10.3.2. Key Executives
10.3.3. Company snapshot
10.3.4. Operating business segments
10.3.5. Product portfolio
10.3.6. Business performance
10.3.7. Key strategic moves and developments
10.4. Vivus LLC.
10.4.1. Company overview
10.4.2. Key Executives
10.4.3. Company snapshot
10.4.4. Operating business segments
10.4.5. Product portfolio
10.4.6. Key strategic moves and developments
10.5. CHEPLAPHARM Arzneimittel GmbH
10.5.1. Company overview
10.5.2. Key Executives
10.5.3. Company snapshot
10.5.4. Operating business segments
10.5.5. Product portfolio
10.6. Pfizer Inc.
10.6.1. Company overview
10.6.2. Key Executives
10.6.3. Company snapshot
10.6.4. Operating business segments
10.6.5. Product portfolio
10.6.6. Business performance
10.7. Rhythm Pharmaceuticals
10.7.1. Company overview
10.7.2. Key Executives
10.7.3. Company snapshot
10.7.4. Operating business segments
10.7.5. Product portfolio
10.7.6. Business performance
10.7.7. Key strategic moves and developments
10.8. Novo Nordisk A/S
10.8.1. Company overview
10.8.2. Key Executives
10.8.3. Company snapshot
10.8.4. Operating business segments
10.8.5. Product portfolio
10.8.6. Business performance
10.8.7. Key strategic moves and developments
10.9. GlaxoSmithKline plc
10.9.1. Company overview
10.9.2. Key Executives
10.9.3. Company snapshot
10.9.4. Operating business segments
10.9.5. Product portfolio
10.9.6. Business performance
10.10. Boehringer Ingelheim International GmbH
10.10.1. Company overview
10.10.2. Key Executives
10.10.3. Company snapshot
10.10.4. Operating business segments
10.10.5. Product portfolio
10.10.6. Business performance
10.10.7. Key strategic moves and developments

LIST OF TABLES
TABLE 01. GLOBAL ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 02. ANTI-OBESITY DRUGS MARKET FOR PRESCRIPTION DRUGS, BY REGION, 2022-2032 ($MILLION)
TABLE 03. ANTI-OBESITY DRUGS MARKET FOR OVER THE COUNTER DRUGS, BY REGION, 2022-2032 ($MILLION)
TABLE 04. GLOBAL ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 05. ANTI-OBESITY DRUGS MARKET FOR CENTRALLY ACTING ANTI-OBESITY DRUGS, BY REGION, 2022-2032 ($MILLION)
TABLE 06. ANTI-OBESITY DRUGS MARKET FOR PERIPHERALLY ACTING ANTI-OBESITY DRUGS, BY REGION, 2022-2032 ($MILLION)
TABLE 07. GLOBAL ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 08. ANTI-OBESITY DRUGS MARKET FOR ORAL ROUTE, BY REGION, 2022-2032 ($MILLION)
TABLE 09. ANTI-OBESITY DRUGS MARKET FOR SUBCUTANEOUS ROUTE, BY REGION, 2022-2032 ($MILLION)
TABLE 10. GLOBAL ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 11. ANTI-OBESITY DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 12. ANTI-OBESITY DRUGS MARKET FOR RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 13. ANTI-OBESITY DRUGS MARKET FOR ONLINE PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 14. ANTI-OBESITY DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 15. NORTH AMERICA ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 17. NORTH AMERICA ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 18. NORTH AMERICA ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 19. NORTH AMERICA ANTI-OBESITY DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 20. U.S. ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 21. U.S. ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 22. U.S. ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 23. U.S. ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 24. CANADA ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 25. CANADA ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 26. CANADA ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 27. CANADA ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 28. MEXICO ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 29. MEXICO ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 30. MEXICO ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 31. MEXICO ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 32. EUROPE ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 33. EUROPE ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 34. EUROPE ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 35. EUROPE ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 36. EUROPE ANTI-OBESITY DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 37. GERMANY ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 38. GERMANY ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 39. GERMANY ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 40. GERMANY ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 41. FRANCE ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 42. FRANCE ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 43. FRANCE ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 44. FRANCE ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 45. UK ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 46. UK ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 47. UK ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 48. UK ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 49. ITALY ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 50. ITALY ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 51. ITALY ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 52. ITALY ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 53. SPAIN ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 54. SPAIN ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 55. SPAIN ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 56. SPAIN ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 57. REST OF EUROPE ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 58. REST OF EUROPE ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 59. REST OF EUROPE ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 60. REST OF EUROPE ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 61. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 62. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 63. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 64. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 65. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 66. JAPAN ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 67. JAPAN ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 68. JAPAN ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 69. JAPAN ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 70. CHINA ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 71. CHINA ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 72. CHINA ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 73. CHINA ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 74. AUSTRALIA ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 75. AUSTRALIA ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 76. AUSTRALIA ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 77. AUSTRALIA ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 78. INDIA ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 79. INDIA ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 80. INDIA ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 81. INDIA ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 82. SOUTH KOREA ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 83. SOUTH KOREA ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 84. SOUTH KOREA ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 85. SOUTH KOREA ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 86. REST OF ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 87. REST OF ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 88. REST OF ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 89. REST OF ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 90. LAMEA ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 91. LAMEA ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 92. LAMEA ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 93. LAMEA ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 94. LAMEA ANTI-OBESITY DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 95. BRAZIL ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 96. BRAZIL ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 97. BRAZIL ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 98. BRAZIL ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 99. SAUDI ARABIA ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 100. SAUDI ARABIA ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 101. SAUDI ARABIA ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 102. SAUDI ARABIA ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 103. SOUTH AFRICA ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 104. SOUTH AFRICA ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 105. SOUTH AFRICA ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 106. SOUTH AFRICA ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 107. REST OF LAMEA ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 108. REST OF LAMEA ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 109. REST OF LAMEA ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 110. REST OF LAMEA ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 111. CURRAX PHARMACEUTICALS LLC: KEY EXECUTIVES
TABLE 112. CURRAX PHARMACEUTICALS LLC: COMPANY SNAPSHOT
TABLE 113. CURRAX PHARMACEUTICALS LLC: PRODUCT SEGMENTS
TABLE 114. CURRAX PHARMACEUTICALS LLC: PRODUCT PORTFOLIO
TABLE 115. CURRAX PHARMACEUTICALS LLC: KEY STRATERGIES
TABLE 116. KVK TECH INC.: KEY EXECUTIVES
TABLE 117. KVK TECH INC.: COMPANY SNAPSHOT
TABLE 118. KVK TECH INC.: PRODUCT SEGMENTS
TABLE 119. KVK TECH INC.: SERVICE SEGMENTS
TABLE 120. KVK TECH INC.: PRODUCT PORTFOLIO
TABLE 121. GELESIS HOLDINGS, INC.: KEY EXECUTIVES
TABLE 122. GELESIS HOLDINGS, INC.: COMPANY SNAPSHOT
TABLE 123. GELESIS HOLDINGS, INC.: SERVICE SEGMENTS
TABLE 124. GELESIS HOLDINGS, INC.: PRODUCT PORTFOLIO
TABLE 125. GELESIS HOLDINGS, INC.: KEY STRATERGIES
TABLE 126. VIVUS LLC.: KEY EXECUTIVES
TABLE 127. VIVUS LLC.: COMPANY SNAPSHOT
TABLE 128. VIVUS LLC.: PRODUCT SEGMENTS
TABLE 129. VIVUS LLC.: SERVICE SEGMENTS
TABLE 130. VIVUS LLC.: PRODUCT PORTFOLIO
TABLE 131. VIVUS LLC.: KEY STRATERGIES
TABLE 132. CHEPLAPHARM ARZNEIMITTEL GMBH: KEY EXECUTIVES
TABLE 133. CHEPLAPHARM ARZNEIMITTEL GMBH: COMPANY SNAPSHOT
TABLE 134. CHEPLAPHARM ARZNEIMITTEL GMBH: SERVICE SEGMENTS
TABLE 135. CHEPLAPHARM ARZNEIMITTEL GMBH: PRODUCT PORTFOLIO
TABLE 136. PFIZER INC.: KEY EXECUTIVES
TABLE 137. PFIZER INC.: COMPANY SNAPSHOT
TABLE 138. PFIZER INC.: PRODUCT SEGMENTS
TABLE 139. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 140. RHYTHM PHARMACEUTICALS: KEY EXECUTIVES
TABLE 141. RHYTHM PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 142. RHYTHM PHARMACEUTICALS: SERVICE SEGMENTS
TABLE 143. RHYTHM PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 144. RHYTHM PHARMACEUTICALS: KEY STRATERGIES
TABLE 145. NOVO NORDISK A/S: KEY EXECUTIVES
TABLE 146. NOVO NORDISK A/S: COMPANY SNAPSHOT
TABLE 147. NOVO NORDISK A/S: PRODUCT SEGMENTS
TABLE 148. NOVO NORDISK A/S: PRODUCT PORTFOLIO
TABLE 149. NOVO NORDISK A/S: KEY STRATERGIES
TABLE 150. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
TABLE 151. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 152. GLAXOSMITHKLINE PLC: PRODUCT SEGMENTS
TABLE 153. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 154. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY EXECUTIVES
TABLE 155. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT
TABLE 156. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT SEGMENTS
TABLE 157. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT PORTFOLIO
TABLE 158. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY STRATERGIES
※본 조사보고서 [글로벌 항비만제 시장 (2023-2032) : 처방약, 일반 의약품] (코드 : ALD23SEP113) 판매에 관한 면책사항을 반드시 확인하세요.
※본 조사보고서 [글로벌 항비만제 시장 (2023-2032) : 처방약, 일반 의약품] 에 대해서 E메일 문의는 여기를 클릭하세요.
※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!

[이하, 관련 보고서 소개]

  • 글로벌 죽상동맥경화증 치료제 시장 (2023-2032) : 항혈소판제 및 항응고제, 콜레스테롤 저하제, ACE 억제제, 기타
    ALD23SEP122 / Allied Market Research / 2023년 4월 / 글로벌 죽상동맥경화증 치료제 시장은 2022년 20,608.51백만 달러에 달했으며 2032년에는 27,711.92백만 달러에 달할 것으로 예상되며, 2023년부터 2032년까지 3%의 연평균 성장률을 보일 것으로 전망됩니다. 죽상동맥경화증은 플라크가 쌓여 동맥 벽이 딱딱해져 정맥이 좁아지는...CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 죽상동맥경화증 치료제 시장, 약제 유형별 CHAPTER 5 : 죽상동맥경화증 치료제 시장, 투여 경로별 CHAPTER 6 : 죽상동맥경화증 치료제 시장, 유통채널별 CHAPTER 7 : 죽상동맥경화증 치료제 시장, 지역별 CHAPTER 8 : 경쟁 현황 CHAPTER 9...
  • 글로벌 근골격계 질환 (MSD) 치료제 시장 (2023-2032) : 진통제, DMARD, 코르티코 스테로이드, 기타
    ALD23SEP123 / Allied Market Research / 2023년 4월 / 글로벌 근골격계 질환 (MSD) 치료제 시장은 2022년 834억 7,424만 달러 규모였으며 2023년부터 2032년까지 4.2%의 연평균 성장률을 보이며 2032년에는 126억 3,022만 달러에 달할 것으로 예상됩니다. 근골격계 질환(MSD)은 근육, 뼈, 관절에 영향을...CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 근골격계 질환(MSD) 치료제 시장, 약품 유형별 CHAPTER 5 : 근골격계 질환(MSD) 치료제 시장, 투여 경로별 CHAPTER 6 : 근골격계 질환(MSD) 치료제 시장, 유통 채널별 CHAPTER 7 : 근골격계 질환(MSD) 치료제 시장, 지역별 CHAPTER 8...
  • 글로벌 제산제 시장 (2023-2032) : 전신성 제산제, 비전신성 제산제
    ALD23SEP116 / Allied Market Research / 2023년 4월 / 글로벌 제산제 시장은 2022년 66억 7,882만 달러 규모였으며 2032년에는 90억 6,847만 달러에 달할 것으로 예상되며 2023년부터 2032년까지 3.1%의 연평균 성장률을 보일 것입니다. 제산제는 속쓰림과 소화불량을 완화하는 데 사용되는 약물입니다. 이러한...CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 제산제 시장, 작용 기전별 CHAPTER 5 : 제산제 시장, 제형별 CHAPTER 6 : 제산제 시장, 유통 채널별 CHAPTER 7 : 제산제 시장, 지역별 CHAPTER 8 : 경쟁 현황 CHAPTER 9 : 기업 정보...
  • 글로벌 림프종 치료제 시장 (2023-2032) : 호지킨 림프종, 비호지킨 림프종
    ALD23SEP105 / Allied Market Research / 2023년 4월 / 세계의 림프종 치료제 시장은 2022년 156억 9,145만 달러로 평가되며 2023년부터 2032년까지 8.4%의 연평균 성장률을 보이며 2032년에는 352억 7,450만 달러에 달할 것으로 예상됩니다. 림프종은 감염 및 기타 질병과 싸우는 데 도움이...CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 림프종 치료제 시장, 질병 유형별 CHAPTER 5 : 림프종 치료제 시장, 치료 유형별 CHAPTER 6 : 림프종 치료제 시장, 투여 경로별 CHAPTER 7 : 림프종 치료제 시장, 유통 채널별 CHAPTER 8 : 림프종 치료제...
  • 글로벌 혈전 용해제 시장 (2023-2032) : 혈전 용해제, 항혈소판제, 항응고제, 항응고제, 기타
    ALD23SEP170 / Allied Market Research / 2023년 6월 / 글로벌 혈전 용해제 시장은 2022년 28,616.4억 달러에서 2023년부터 2032년까지 8.2%의 연평균 성장률로 성장하여 2032년에는 60,009.20억 달러에 달할 것으로 예상됩니다.혈전 용해제 또는 섬유소 용해제라고도 하는 혈전 용해제는 혈전증이라는 의학적 질환에서 혈전을...CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 혈전 용해제 시장, 제품별 CHAPTER 5 : 혈전 용해제 시장, 질환별 CHAPTER 6 : 혈전 용해제 시장, 투여 경로별 CHAPTER 7 : 혈전 용해제 시장, 유통 채널별 CHAPTER 8 : 혈전 용해제 시장, 지역별...